

Supporting Information for

In Vivo Targeting of Metabolically Labeled Cancers with Ultra-Small Silica Nanoconjugates

Hua Wang¹, Li Tang¹, Yang Liu¹, Iwona Teresa Dobrucki², Lawrence W. Dobrucki³, Lichen Yin⁴✉, Jianjun Cheng¹✉

1. Department of Materials Science and Engineering, University of Illinois at Urbana-Champaign, Urbana, Illinois 61801, USA.
2. Molecular Imaging Laboratory, Beckman Institute for Advanced Science and Technology, University of Illinois at Urbana-Champaign, Urbana, Illinois 61801, USA.
3. Department of Bioengineering, University of Illinois at Urbana-Champaign, Urbana, Illinois 61801, USA.
4. Jiangsu Key Laboratory for Carbon-Based Functional Materials & Devices, Institute of Functional Nano & Soft Materials (FUNSOM), Collaborative Innovation Center of Suzhou Nano Science and Technology, Soochow University, Suzhou 215123, Jiangsu, China.

✉ Corresponding authors: jianjunc@illinois.edu, lcyin@suda.edu.cn




Figure S1. Schematic illustration of the metabolic labeling processes of Ac₄ManDBCO.




Figure S2. TEM image of azido-/Cy5-NCs. Scale bar represents 50 nm.




Figure S3. CLSM images of tumor tissue sections harvested from mice pretreated with Ac₄ManDBCO (5 mg/kg) and PBS, respectively once daily for three days. Tumor tissue sections were labeled with Cy5-azide (red) for 30 min. Cell nuclei were stained with DAPI (blue). Scale bar represents 10 μ m.